LI Jia, HAN Xiao-lu, SONG Shi-yu, LIN Jin-tao, TANG Zhi-qiang, WANG Zeng-ming, XU Liang, ZHENG Ai-ping. Progress on antisense oligonucleotide in the field of antibacterial therapyJ. Acta Pharmaceutica Sinica, 2025, 60(2): 337-347. DOI: 10.16438/j.0513-4870.2024-0607
Citation: LI Jia, HAN Xiao-lu, SONG Shi-yu, LIN Jin-tao, TANG Zhi-qiang, WANG Zeng-ming, XU Liang, ZHENG Ai-ping. Progress on antisense oligonucleotide in the field of antibacterial therapyJ. Acta Pharmaceutica Sinica, 2025, 60(2): 337-347. DOI: 10.16438/j.0513-4870.2024-0607

Progress on antisense oligonucleotide in the field of antibacterial therapy

  • With the widespread use of antibiotics, drug-resistant bacterial infections have become a significant threat to human health. Finding new antibacterial strategies that can effectively control drug-resistant bacterial infections has become an urgent task. Unlike small molecule drugs that target bacterial proteins, antisense oligonucleotide (ASO) can target genes related to bacterial resistance, pathogenesis, growth, reproduction and biofilm formation. By regulating the expression of these genes, ASO can inhibit or kill bacteria, providing a novel approach for the development of antibacterial drugs. To overcome the challenge of delivering antisense oligonucleotide into bacterial cells, various drug delivery systems have been applied in this field, including cellpenetrating peptides, lipid nanoparticles and inorganic nanoparticles, which have injected new momentum into the development of antisense oligonucleotide in the antibacterial realm. This review summarizes the current development of small nucleic acid drugs, the antibacterial mechanisms, targets, sequences and delivery vectors of antisense oligonucleotide, providing a reference for the research and development of antisense oligonucleotide in the treatment of bacterial infections.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return